ORYZON Closes € 5.3 Million (6 M USD) in additional Debt Financing
BARCELONA, SPAIN and CAMBRIDGE MA.
• With these funds the company completes its Global Funding of € 32 Million (36 Million USD)
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has closed a second tranche of Debt Funding round of 5.3 Million Euros (5.9 Million USD). These proceeds come on top of the 10.5 Million Euros (11.6 Million USD) raised in May.In total, Oryzon have raised more than 32 Million Euros (35.5 Million USD) since July 2015.